Investors focused on the Medical space have likely heard of DexCom (DXCM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is one of 905 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 25.60% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, DXCM has gained about 7.71% so far this year. Meanwhile, stocks in the Medical group have gained about 2.22% on average. This shows that DexCom is outperforming its peers so far this year.
Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 96 individual stocks and currently sits at #161 in the Zacks Industry Rank. This group has gained an average of 3.16% so far this year, so DXCM is performing better in this area.
Investors in the Medical sector will want to keep a close eye on DXCM as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of DexCom (DXCM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
DexCom is one of 905 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DXCM is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for DXCM's full-year earnings has moved 25.60% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, DXCM has gained about 7.71% so far this year. Meanwhile, stocks in the Medical group have gained about 2.22% on average. This shows that DexCom is outperforming its peers so far this year.
Looking more specifically, DXCM belongs to the Medical - Instruments industry, a group that includes 96 individual stocks and currently sits at #161 in the Zacks Industry Rank. This group has gained an average of 3.16% so far this year, so DXCM is performing better in this area.
Investors in the Medical sector will want to keep a close eye on DXCM as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on DXCM - FREE